Literature DB >> 33384409

NAD+ metabolism, stemness, the immune response, and cancer.

Lola E Navas1,2, Amancio Carnero3,4.   

Abstract

NAD+ was discovered during yeast fermentation, and since its discovery, its important roles in redox metabolism, aging, and longevity, the immune system and DNA repair have been highlighted. A deregulation of the NAD+ levels has been associated with metabolic diseases and aging-related diseases, including neurodegeneration, defective immune responses, and cancer. NAD+ acts as a cofactor through its interplay with NADH, playing an essential role in many enzymatic reactions of energy metabolism, such as glycolysis, oxidative phosphorylation, fatty acid oxidation, and the TCA cycle. NAD+ also plays a role in deacetylation by sirtuins and ADP ribosylation during DNA damage/repair by PARP proteins. Finally, different NAD hydrolase proteins also consume NAD+ while converting it into ADP-ribose or its cyclic counterpart. Some of these proteins, such as CD38, seem to be extensively involved in the immune response. Since NAD cannot be taken directly from food, NAD metabolism is essential, and NAMPT is the key enzyme recovering NAD from nicotinamide and generating most of the NAD cellular pools. Because of the complex network of pathways in which NAD+ is essential, the important role of NAD+ and its key generating enzyme, NAMPT, in cancer is understandable. In the present work, we review the role of NAD+ and NAMPT in the ways that they may influence cancer metabolism, the immune system, stemness, aging, and cancer. Finally, we review some ongoing research on therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33384409      PMCID: PMC7775471          DOI: 10.1038/s41392-020-00354-w

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  332 in total

Review 1.  The cancer stem-cell signaling network and resistance to therapy.

Authors:  A Carnero; Y Garcia-Mayea; C Mir; J Lorente; I T Rubio; M E LLeonart
Journal:  Cancer Treat Rev       Date:  2016-07-09       Impact factor: 12.111

2.  The sirtuin SIRT6 regulates lifespan in male mice.

Authors:  Yariv Kanfi; Shoshana Naiman; Gail Amir; Victoria Peshti; Guy Zinman; Liat Nahum; Ziv Bar-Joseph; Haim Y Cohen
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

3.  Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.

Authors:  Hanwen Zhang; Ning Zhang; Ying Liu; Peng Su; Yiran Liang; Yaming Li; Xiaolong Wang; Tong Chen; Xiaojin Song; Yuting Sang; Yi Duan; Jiashu Zhang; Lijuan Wang; Bing Chen; Wenjing Zhao; Haiyang Guo; Zhaojian Liu; Guohong Hu; Qifeng Yang
Journal:  Cancer Res       Date:  2019-04-02       Impact factor: 12.701

4.  CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism.

Authors:  Juliana Camacho-Pereira; Mariana G Tarragó; Claudia C S Chini; Veronica Nin; Carlos Escande; Gina M Warner; Amrutesh S Puranik; Renee A Schoon; Joel M Reid; Antonio Galina; Eduardo N Chini
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

5.  Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages.

Authors:  Cláudia A Fernandes; Laurence Fievez; Audrey M Neyrinck; Nathalie M Delzenne; Fabrice Bureau; Rita Vanbever
Journal:  Biochem Biophys Res Commun       Date:  2012-03-24       Impact factor: 3.575

Review 6.  Dynamics of NAD-metabolism: everything but constant.

Authors:  Christiane A Opitz; Ines Heiland
Journal:  Biochem Soc Trans       Date:  2015-12       Impact factor: 5.407

Review 7.  Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

Authors:  Jessica B Katz; Alexander J Muller; George C Prendergast
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 8.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases.

Authors:  Claudio Franceschi; Judith Campisi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-06       Impact factor: 6.053

9.  PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.

Authors:  Nathan R Fons; Ranjini K Sundaram; Gregory A Breuer; Sen Peng; Ryan L McLean; Aravind N Kalathil; Mark S Schmidt; Diana M Carvalho; Alan Mackay; Chris Jones; Ángel M Carcaboso; Javad Nazarian; Michael E Berens; Charles Brenner; Ranjit S Bindra
Journal:  Nat Commun       Date:  2019-08-22       Impact factor: 17.694

10.  The membrane of peroxisomes in Saccharomyces cerevisiae is impermeable to NAD(H) and acetyl-CoA under in vivo conditions.

Authors:  C W van Roermund; Y Elgersma; N Singh; R J Wanders; H F Tabak
Journal:  EMBO J       Date:  1995-07-17       Impact factor: 11.598

View more
  43 in total

1.  Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications.

Authors:  Priyanka Banerjee; Elizabeth A Olmsted-Davis; Anita Deswal; Minh Th Nguyen; Efstratios Koutroumpakis; Nicholas L Palaskas; Steven H Lin; Sivareddy Kotla; Cielito Reyes-Gibby; Sai-Ching J Yeung; Syed Wamique Yusuf; Momoko Yoshimoto; Michihiro Kobayashi; Bing Yu; Keri Schadler; Joerg Herrmann; John P Cooke; Abhishek Jain; Eduardo Chini; Nhat-Tu Le; Jun-Ichi Abe
Journal:  J Cardiovasc Aging       Date:  2022-04-29

Review 2.  Emerging roles of cystathionine β-synthase in various forms of cancer.

Authors:  Kelly Ascenção; Csaba Szabo
Journal:  Redox Biol       Date:  2022-05-10       Impact factor: 10.787

3.  A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.

Authors:  Niels Böhnke; Markus Berger; Nils Griebenow; Antje Rottmann; Michael Erkelenz; Stefanie Hammer; Sandra Berndt; Judith Günther; Antje M Wengner; Beatrix Stelte-Ludwig; Christoph Mahlert; Simone Greven; Lisa Dietz; Hannah Jörißen; Naomi Barak; Ulf Bömer; Roman C Hillig; Uwe Eberspaecher; Jörg Weiske; Anja Giese; Dominik Mumberg; Carl Friedrich Nising; Hilmar Weinmann; Anette Sommer
Journal:  Bioconjug Chem       Date:  2022-06-03       Impact factor: 6.069

Review 4.  The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.

Authors:  Máté A Demény; László Virág
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

Review 5.  Role of PGC-1α in the Mitochondrial NAD+ Pool in Metabolic Diseases.

Authors:  Jin-Ho Koh; Jong-Yeon Kim
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 6.  A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity.

Authors:  Eleanor L Hopkins; Weixi Gu; Bostjan Kobe; Michael P Coleman
Journal:  Front Mol Biosci       Date:  2021-07-08

7.  Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.

Authors:  Veerle W Daniels; Jason J Zoeller; Nick van Gastel; Kelley E McQueeney; Salma Parvin; Danielle S Potter; Geoffrey G Fell; Vinícius G Ferreira; Binyam Yilma; Rajat Gupta; Johan Spetz; Patrick D Bhola; Jennifer E Endress; Isaac S Harris; Emanuel Carrilho; Kristopher A Sarosiek; David T Scadden; Joan S Brugge; Anthony Letai
Journal:  Sci Signal       Date:  2021-06-08       Impact factor: 8.192

Review 8.  NAD+ Metabolism, Metabolic Stress, and Infection.

Authors:  Benjamin Groth; Padmaja Venkatakrishnan; Su-Ju Lin
Journal:  Front Mol Biosci       Date:  2021-05-19

Review 9.  Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer.

Authors:  Renata Novak Kujundžić; Marin Prpić; Nikola Đaković; Nina Dabelić; Marko Tomljanović; Anamarija Mojzeš; Ana Fröbe; Koraljka Gall Trošelj
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 10.  Epigenetic strategies to boost CAR T cell therapy.

Authors:  Behnia Akbari; Navid Ghahri-Saremi; Tahereh Soltantoyeh; Jamshid Hadjati; Saba Ghassemi; Hamid Reza Mirzaei
Journal:  Mol Ther       Date:  2021-08-06       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.